134. Azizi Kutenaei M, Hosseini Teshnizi S, Ghaemmaghami P, Eini F, Roozbeh N. The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021 Apr;25(7):3105-3115. doi: 10.26355/eurrev_202104_25565.
135. Zarezadeh M, Dehghani A, Faghfouri AH, Radkhah N, Naemi Kermanshahi M, Hamedi Kalajahi F, Mohammadzadeh Honarvar N, Ghoreishi Z, Ostadrahimi A, Ebrahimi Mamaghani M. Inositol supplementation and body mass index: A systematic review and meta-analysis of randomized clinical trials. Obes Sci Pract. 2021 Oct 22;8(3):387-397. doi: 10.1002/osp4.569.
136. Jethaliya H, Gajjar N, Patel V, Deshpande S, Patel R. Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial. Reprod Sci. 2022 Aug;29(8):2282-2298. doi: 10.1007/s43032-022-00933-y.
137. Bahri Khomami M, Teede HJ, Joham AE, Moran LJ, Piltonen TT, Boyle JA. Clinical management of pregnancy in women with polycystic ovary syndrome: An expert opinion. Clin Endocrinol (Oxf). 2022 Aug;97(2):227-236. doi: 10.1111/cen.14723.
138. Bahri Khomami M, Joham AE, Boyle JA, et al. Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity—a systematic review, meta‐analysis, and meta‐regression. Obesity Reviews. 2019;20(5):659‐674.
139. Wendland EM, Duncan BB, Belizán JM, Vigo A, Schmidt MI. Gestational diabetes and pre‐eclampsia: common antecedents? Arquivos Brasil Endocrinol Metab. 2008;52:975‐984.
140. Национальные медицинские критерии приемлемости методов контрацепции. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ, 5 издание, 2015» Москва 2023
141. Different kinds of oral contraceptive pills in polycystic ovary syndrome: A systematic review and meta-analysis. July 2023. European Journal of Endocrinology 189(1). DOI:10.1093/ejendo/lvad082 Maria Forslund, Johanna Melin, Simon Alesi,Helena Teede, European Journal oEndocrinology, 2023, 189, S1–S16
141. Amiri M, Bidhendi-Yarandi R, Fallahzadeh A, Marzban Z, Ramezani Tehrani F. Risk of endometrial, ovarian, and breast cancers in women with polycystic ovary syndrome: A systematic review and meta-analysis. Int J Reprod Biomed. 2022;20(11):893-914.
142. Li Z, Wang YH, Wang LL, et al. Polycystic ovary syndrome and the risk of endometrial, ovarian and breast cancer: An updated meta-analysis. Scott Med J. 2022;67(3):109-120.
143. American association of clinical endocrinologists, american college of endocrinology, and androgen excess and pcos society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome/ N. F. Goodman [et al.] // Endocr Pract. – 2015.
144. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018 Aug;110(3):364-379
145. Marshall W. A., Tanner J. M. Variations in pattern of pubertal changes in girls //Archives of disease in childhood. – 1969. – Т. 44. – №. 235. – С. 291.
146. Munro M. G. et al. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions //International Journal of Gynecology & Obstetrics. – 2018
147. Suturina L, Lizneva D, Atalyan A, Lazareva L, et al Establishing Normative Values to Determine the Prevalence of Biochemical Hyperandrogenism in Premenopausal Women of Different Ethnicities from Eastern Siberia. Diagnostics (Basel). 2022
148. Belsti Y, Enticott J, Azumah R, Tay CT, Moran L, Ma RCW, Joham AE, Laven J, Teede H, Mousa A. Diagnostic accuracy of oral glucose tolerance tests, fasting plasma glucose and haemoglobin A1c for type 2 diabetes in women with polycystic ovary syndrome: A systematic review and meta-analysis. Diabetes Metab Syndr. 2024 Mar;18(3):102970. doi: 10.1016/j.dsx.2024.102970. Epub 2024 Feb 28. PMID: 38442646.
149. Paulus GF1, de Vaan LE, Verdam FJ, Bouvy ND, Ambergen TA, van Heurn LW. Bariatric surgery in morbidly obese adolescents: a systematic review and meta-analysis. Obes Surg. 2015 May;25(5):860-78. doi: 10.1007/s11695-015-1581-2.
150. Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. Surg Obes Relat Dis 2022;18:1345-56.
151. Goldberg A, Graca S, Liu J, Rao V, Witchel SF, Pena A, Li R, Mousa A, Tay CT, Pattuwage L, Teede H, Yildiz BO, Ee C. Anti-obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obes Rev. 2024 May;25(5):e13704. doi: 10.1111/obr.13704.
152. Wang FF, Wu Y, Zhu YH, Ding T, Batterham RL, Qu F, Hardiman PJ. Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis. Obes Rev. 2018 Oct;19(10):1424-1445. doi: 10.1111/obr.12720.